Feature

Medical marijuana’s ‘Catch-22’: Federal limits on research hinder patients’ relief


 


Without clear answers, hospitals, doctors, and patients are left to their own devices, which can result in poor treatment and needless suffering.

Hospitals and other medical facilities have to decide what to do with newly hospitalized patients who normally take medical marijuana at home.

Some have a “don’t ask, don’t tell” approach, said Dr. Devinsky, who sometimes advises his patients to use it. Others ban its use and substitute opioids or other prescriptions.

Young adults, for instance, have had to stop taking cannabidiol compounds for their epilepsy because they’re in federally funded group homes, said Dr. Devinsky, the director of New York University’s Langone Comprehensive Epilepsy Center.

“These kids end up getting seizures again,” he said. “This whole situation has created a hodgepodge of insanity.”

Pages

Recommended Reading

Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Rheumatology
Opioid prescriptions got shorter in 2017
MDedge Rheumatology
The case for being open-minded about medical marijuana
MDedge Rheumatology
Intramuscular steroid injection reduced hip OA pain up to 12 weeks
MDedge Rheumatology
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Rheumatology
Is kratom the answer to the opioid crisis?
MDedge Rheumatology
FDA recalls kratom products for salmonella contamination
MDedge Rheumatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Rheumatology
CMS finalizes measures to help combat opioid crisis
MDedge Rheumatology
Life and health are not even across the U.S.
MDedge Rheumatology